Federal Oversight of Laboratory-Developed Tests in Limbo: What’s the Regulatory & Legislative Outlook for LDTs?
Instructor:
Dennis Weissman
Product ID: 706769
Training Level: Intermediate
- Duration: 60 Min
Why Should You Attend:
Though LDTs remain subject to the Clinical Laboratory Improvement Amendment (CLI A) requirements, the current uncertainty regarding FDA’s role in regulating LDTs raises the stakes for legislative reform. Pending legislation which would allow the FDA to maintain oversight of all diagnostics including LDTs while setting regulatory requirements based on a test’s risks, not where it was made will be detailed in this presentation.
Areas Covered in the Webinar:
- Overview of Laboratory Developed Tests (LDTs)
- FDA’s position for regulating LDTs including its handling of Emergency Use Authorizations (EUAs) for lab developed COVID tests.
- Why an HHS decision that FDA not require pre- market review of LDTs absent notice-and-comment rulmaking raises key questions about future oversight of LDTs.
- Pros & cons of having CLIA as sole oversight of LDTs
- Differing legislative approaches for determining the role of CLIA and FDA in regulating LDTs
- Key features of VALID and VITAL Acts and industry reaction
- Outlook for pending legislation relating to FDA oversight by LDTs
- Why current regulatory status of LDTs remains in limbo & timeline for clarification of FDA’s authority
Who Will Benefit:
- Laboratory medical & administrative directors and managers in academic, hospital & research labs
- President, CEOs, COOs, lab medical directors, administrative directors in independent labs
- Chief compliance officers, General Counsel & VP and senior managers of regulatory affairs
- General counsels & VP for Regulatory Affairs for commercial diagnostic tests manufacturers
Dennis Weissman
President, Dennis Weissman and Associates LLC
Dennis is President of Dennis Weissman & Associates, LLC, a consultancy which provides market intelligence, business leadership and public policy guidance and M&A advisory services to diagnostic and health care organizations & related interests. He previously founded and served as publisher of Washington G-2 Reports (now G2 Intelligence), an information company that reports on the U.S. clinical laboratory and pathology sectors. His expertise is in Medicare and national health care policies and trends as well as business and financial issues affecting the health care industry
More Training By Experts
- How Medicare's Market-Based Payment System Is Upending the U.S. Clinical Laboratory Market
- Where FDA Is Heading in Regulating Laboratory-Developed Tests
- The Latest in CLIA Compliance for Clinical Labs
- Health Reform Turbulence in the Trump Era: Market Impact and 2018 Outlook
- How Medicare's Market-Based Payment System for Laboratory Services Will Change the Industry's Competitive Dynamics In 2019
Refund Policy
Our refund policy is governed by individual products and services refund policy mentioned against each of offerings. However in absence of specific refund policy of an offering below refund policy will be effective.
Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. ComplianceOnline would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange. Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time. On-Demand Recording purchases will not be refunded as it is available for immediate streaming. However if you are not able to view the webinar or you have any concern about the content of the webinar please contact us at below email or by call mentioning your feedback for resolution of the matter. We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email [email protected] call +1-888-717-2436 (Toll Free).
